GlassScriptPhysician profile
Alyssa Loftus
NPI 1346894623
$3,407.50
in general payments reported to CMS, 2019-2025
26 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $279 · 2023: $1,047 · 2024: $1,041 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.58 | 2022-2025 | |
| Alkermes, INC. | $331.37 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $307.00 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $269.18 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $253.76 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $181.48 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $172.12 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $146.52 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $142.37 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $136.91 | 2024-2025 | Invega Sustenna, Spravato, Invega |
| Supernus Pharmaceuticals, INC. | $119.87 | 2022-2023 | Qelbree |
| Bausch Health US, LLC | $96.87 | 2023-2024 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $87.15 | 2022-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $70.78 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $68.81 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $64.86 | 2023-2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $53.53 | 2025 | Fanapt, Hetlioz |
| Corium, LLC | $47.76 | 2025 | Azstarys |
| Vertical Pharmaceuticals, LLC | $45.19 | 2024 | Relexxii |
| Tempus Ai, INC | $40.54 | 2024 | |
| Sunovion Pharmaceuticals INC. | $24.93 | 2022 | |
| Tris Pharma INC | $23.00 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $21.15 | 2023 | Gralise |
| Noven Therapeutics, LLC | $18.63 | 2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $18.50 | 2022 | |
| Neos Therapeutics, LP | $14.64 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.